Robbie Woodman

Operates genome editing company that develops genetic medicines and cell therapies for severe diseases

Panakes Partners invests in small and mid-market companies located across the globe primarily in Europe. The firm targets companies operating in the life sciences sector. It participates in early stage capital requirements.

IIIM is an active manager which invests in technology businesses based on intellectual property from Imperial College. The company also invests in companies that have been through the incubation process managed by the Imperial Innovations' New Ventures team. The firm leads or co-leads investment rounds in technology companies across all stages of development in the healthcare, energy, environment and emerging technology sectors. Companies seeking first round funding and beyond are expected to have demonstrated that they have recruited of an experienced CEO and CTO, have a functioning board including an experienced Chairman and at least one non-executive director appointed by IIIM, have financial controls and responsible financial management, have resolved initial intellectual property technical risk, have a clear, credible and commercial business plan and have identified a location for the company to achieve full independence IIIM works toward exits through trade sales, mergers or IPOs.

Develops therapeutics

Takeda Ventures invests in companies located across the globe. The firm focuses on high-caliber, therapeutic, platform-based companies. It provides financing for early stage capital requirements.

Operates as a biotechnology company developing allogeneic, off the shelf CAR-NK cell therapies for cancer treatment

Sofinnova Partners invests in companies located in the United States, France and Europe. The firm targets companies operating in the fields of life sciences and technology sectors. It provides financing for seed and early stage capital requirements.

IIIM is an active manager which invests in technology businesses based on intellectual property from Imperial College. The company also invests in companies that have been through the incubation process managed by the Imperial Innovations' New Ventures team. The firm leads or co-leads investment rounds in technology companies across all stages of development in the healthcare, energy, environment and emerging technology sectors. Companies seeking first round funding and beyond are expected to have demonstrated that they have recruited of an experienced CEO and CTO, have a functioning board including an experienced Chairman and at least one non-executive director appointed by IIIM, have financial controls and responsible financial management, have resolved initial intellectual property technical risk, have a clear, credible and commercial business plan and have identified a location for the company to achieve full independence IIIM works toward exits through trade sales, mergers or IPOs.